Desktop 3D printing of controlled release pharmaceutical bilayer tablets

被引:391
作者
Khaled, Shaban A. [1 ]
Burley, Jonathan C. [1 ]
Alexander, Morgan R. [1 ]
Roberts, Clive J. [1 ,2 ]
机构
[1] Univ Nottingham, Sch Pharm, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England
[2] Univ Nottingham, Nottingham Nanotechnol & Nanosci Ctr, Nottingham NG7 2RD, England
关键词
Guaifenesin bilayer tablets; 3D printing; Guaifenesin; Controlled release; Personalized medicine; ORAL DOSAGE FORMS; PERSONALIZED MEDICINE; STABILITY;
D O I
10.1016/j.ijpharm.2013.11.021
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Three dimensional (3D) printing was used as a novel medicine formulation technique for production of viable tablets capable of satisfying regulatory tests and matching the release of standard commercial tablets. Hydroxypropyl methylcellulose (HPMC 2208) (MethocelTm K1 OOM Premium) and poly(acrylic acid) (PAA) (Carbopol 974P NF) were used as a hydrophilic matrix for a sustained release (SR) layer. Hypromellose (HPMC 2910) was used as a binder while microcrystalline cellulose (MCC) (Pharmacel 102) and sodium starch glycolate (SSG) (Primojer) were used as disintegrants for an immediate release (IR) layer. Commercial guaifenesin bi-layer tablets (GBT) were used as a model drug (Mucinex) for this study. There was a favourable comparison of release of the active guaifenesin from the printed hydrophilic matrix compared with the commercially available GBT. The printed formulations were also evaluated for physical and mechanical properties such as weight variation, friability, hardness and thickness as a comparison to the commercial tablet and were within acceptable range as defined by the international standards stated in the United States Pharmacopoeia (USP). All formulations (standard tablets and 3D printed tablets) showed Korsmeyer-Peppas n values between 0.27 and 0.44 which indicates Fickian diffusion drug release through a hydrated HPMC gel layer. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 34 条
[1]
Abd-Allah FI, 2010, DRUG DISCOV THER, V4, P267
[2]
[Anonymous], 2010, INT J RES PHARM SCI
[3]
[Anonymous], 2010, J PHARM SCI RES
[4]
[Anonymous], 2000, US PHARM 24
[5]
Blume RW, 2002, Guaifenesin sustained release formulation and tablets, Patent No. [US 6,372,252 B1, 6372252, 6,372,252 B1]
[6]
Bushra R, 2008, PAK J PHARM SCI, V21, P113
[7]
Dash S, 2010, ACTA POL PHARM, V67, P217
[8]
Davies P., 2009, PHARM PREFORMULATION, P12
[9]
Foltmann H., 2008, Drug Delivery Technology, V8, P22
[10]
Grassi Mario, 2005, Current Drug Delivery, V2, P97, DOI 10.2174/1567201052772906